ROCKVILLE, MD, October 16, 2023 – AIM-HI Accelerator Fund is pleased to announce that the winners of the 2023 Women’s Venture Competition are March Biosciences and its CEO, Sarah Hein, Ph.D., as the First Prize with Distinction and Degron Therapeutics and its Co-founder and CEO, Lily Zou, Ph.D., MBA as the Second Prize. Blue-ribbon judge committee members selected them from a pool of 71 female-led, early-stage oncology companies across 15 countries. The Winners will be recognized at a Luncheon Award Ceremony with certificates and honorariums during the 2023 Global Summit and Award Ceremonies for Cancer Research & Entrepreneurship, co-hosted by AIM-HI and the National Foundation for Cancer Research on October 21, 2023, at the National Press Club in Washington, DC. March Biosciences has developed the MB-105 T-cell therapy for T-cell lymphoma (TCL) and T-cell acute lymphoblastic leukemia (T-ALL), indications with few treatment options and an exceptionally poor prognosis which leave patients little room for hope. The Phase 1 clinical trial has demonstrated strong efficacy and safety signals, with multiple long-term survivors in remission years after treatment. “I am truly humbled to accept this prestigious award on behalf of March Biosciences. The journey has been one of passion, perseverance, and collaboration building off the breakthrough innovations from leading scientists at Baylor College of Medicine. This recognition from AIM-HI is an acknowledgment of our hard work and an affirmation of our technology platform,” said Dr. Hein. “Thank you for this incredible honor, and together, we will continue to push the boundaries of what’s possible in the fight against cancer.” Degron Therapeutics has designed and synthesized a unique molecular glue degrader (MGD) compound library known as the GlueXplorer platform. It uses its platform in combination with phenotypic screening, proteomic screening, and AI to accelerate the development of novel drugs for previously undruggable targets in oncology. Its lead program, a first-in-class MGD of an “undruggable” RNA binding protein which regulates critical cancer survival pathways, will enter clinical trials for multiple oncology indications with high unmet need. In addition to the first and second-place winners, Delee was selected as The 2023 People’s Choice for “Best Pitch” by a public audience voting for their favorite pitch presentation during the 2023 Women’s Venture Competition selection process. Led by 26-year-old Liza Velarde, Co-founder and CEO, Delee has developed a circulating tumor cell (CTC) detection technology (CytoCatchTM) involving a simple blood test and lab-on-a-chip technology for early cancer detection and monitoring of applied treatment effectiveness. AIM-HI launched the Women’s Venture Competition in 2020 to empower women scientist-entrepreneurs who are underfunded and underserved in the life science industry and create a sustaining impact for cancer patients through their worldwide ventures. AIM-HI harnesses the collective efforts of donors, visionary scientists, and entrepreneurs through its venture philanthropy approach to advance the development of promising discoveries to breakthrough therapies for patients. “In an environment where numerous medical breakthroughs and transformative technologies struggle to progress into viable treatments due to limited funding for early-stage enterprises often deemed too risky for conventional venture capital or biopharmaceutical firms, the hurdles are even greater for women-led ventures,” said Sujuan Ba, Ph.D., Co-founder and CEO of AIM-HI. “The Women’s Venture Competition’s goal of bolstering women-led startups at […]
The post The AIM-HI Accelerator Fund Recognizes, Honors, and Congratulates Its 2023 Women’s Venture Competition Top Winners appeared first on NFCR.